|
Market Closed -
Nasdaq
00:00:00 14/11/2026 +03
|
5-day change | 1st Jan Change | ||
| 5.660 USD | -0.35% |
|
-10.02% | -7.97% |
| 11-11 | Myriad Genetics, Inc. Presents at 2026 UBS Global Healthcare Conference, Nov-10-2026 01:15 PM | |
| 11-05 | Myriad Genetics, Inc., Q3 2026 Earnings Call, Nov 04, 2026 |
Company Valuation: Myriad Genetics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,204 | 1,176 | 1,697 | 1,248 | 573.3 | 544.8 | - | - |
| Change | - | -46.65% | 44.34% | -26.46% | -54.07% | -4.96% | - | - |
| Enterprise Value (EV) 1 | 1,864 | 1,061 | 1,595 | 1,185 | 543.6 | 495.9 | 477.1 | 444.2 |
| Change | - | -43.09% | 50.32% | -25.67% | -54.14% | -8.78% | -3.79% | -6.9% |
| P/E | -78.9x | -10.4x | -6.02x | -9.72x | -1.56x | -3.41x | -4.29x | -4.62x |
| PBR | 2.28x | 1.33x | 2.2x | 1.79x | 1.56x | 1.59x | 1.68x | 1.62x |
| PEG | - | -0x | -0x | 0.2x | -0x | 0.1x | 0.2x | 0.64x |
| Capitalization / Revenue | 3.19x | 1.73x | 2.25x | 1.49x | 0.7x | 0.69x | 0.74x | 0.71x |
| EV / Revenue | 2.7x | 1.56x | 2.12x | 1.42x | 0.66x | 0.63x | 0.65x | 0.58x |
| EV / EBITDA | 25.9x | -50.5x | -253x | 29.3x | 14x | -9.2x | -22.6x | -26.5x |
| EV / EBIT | 205x | -32.3x | -62.5x | 54.4x | 36x | -6.66x | -6.51x | -4.93x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.35 | -1.39 | -3.18 | -1.41 | -3.95 | -1.66 | -1.32 | -1.225 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 690.6 | 678.4 | 753.2 | 837.6 | 824.5 | 785.1 | 737.7 | 763.4 |
| EBITDA 1 | 71.9 | -21 | -6.3 | 40.4 | 38.9 | -53.87 | -21.1 | -16.75 |
| EBIT 1 | 9.1 | -32.8 | -25.5 | 21.8 | 15.1 | -74.46 | -73.28 | -90.16 |
| Net income 1 | -27.2 | -112 | -263.3 | -127.3 | -365.9 | -152.1 | -93.23 | -118.1 |
| Net Debt 1 | -339.8 | -114.9 | -102.4 | -62.8 | -29.7 | -48.99 | -67.76 | -100.7 |
| Reference price 2 | 27.600 | 14.510 | 19.140 | 13.710 | 6.150 | 5.660 | 5.660 | 5.660 |
| Nbr of stocks (in thousands) | 79,855 | 81,034 | 88,669 | 91,035 | 93,214 | 95,922 | - | - |
| Announcement Date | 2/24/22 A | 2/28/23 A | 2/27/24 A | 2/24/25 A | 2/23/26 A | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.42x | 0.63x | -9.2x | -.--% | 545M | |
| 35.48x | 4.19x | 15.73x | 2.42% | 186B | |
| 21.86x | 3.71x | 13.29x | 2.81% | 124B | |
| 26.94x | 4.79x | 16.44x | 1.15% | 119B | |
| 31.57x | 3.04x | 12.28x | 2.26% | 91.43B | |
| 18.53x | 0.22x | 13.79x | 0.68% | 66.67B | |
| 43.97x | 3.87x | 13.18x | 1.94% | 58.76B | |
| 46.33x | 11.64x | 32.65x | -.--% | 54.99B | |
| 28.86x | 7.15x | 18.14x | 1.39% | 49.93B | |
| 52.13x | 1.44x | 13.34x | -.--% | 35.13B | |
| Average | 30.23x | 4.07x | 13.96x | 1.26% | 79B | |
| Weighted average by Cap. | 31.84x | 4.30x | 15.91x | 1.74% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- MYGN Stock
- Valuation Myriad Genetics, Inc.
Select your edition
All financial news and data tailored to specific country editions
